Nuvig Therapeutics Stock
Nuvig Therapeutics is developing a new class of immunomodulatory therapies aimed at treating autoimmune diseases without broadly suppressing the immune system. Its platform targets endogenous pathways that regulate inflammation, with the goal of delivering disease control while preserving immune function.
For more Nuvig Therapeutics stock information, or to buy or sell private shares, sign up for a MicroVentures account.
Management Team
| Pamela Conley, Ph.D. Co-Founder, Chief Scientific Officer, & Founding Chief Executive Officer |
| Alan Glicklich, M.D. Chief Medical Officer |
